Actuate Therapeutics, Inc. Fair Value Adjustment of Warrants
Actuate Therapeutics, Inc. (ACTU) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-03-26
- Actuate Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $0.00.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for fiscal 2024 was $78.90K, a 1.15% decline from fiscal 2023.
- Actuate Therapeutics, Inc. fair value adjustment of warrants for fiscal 2023 was $79.82K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | -$193.95K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | -$193.95K derived: sum of 3 quarters · filed 2026-03-26 | $46.39K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$193.95K derived: sum of 2 quarters · filed 2026-03-26 | $46.39K derived: sum of 3 quarters · filed 2026-03-26 | $78.90K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$193.95K 10-Q · filed 2025-11-13 | $46.39K derived: sum of 2 quarters · filed 2025-11-13 | $78.90K 10-Q · filed 2025-11-13 | $130.50K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $240.34K 10-Q · filed 2025-08-14 | $272.85K 10-Q · filed 2025-08-14 | $324.45K derived: sum of 3 quarters · filed 2025-08-14 | $307.59K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $32.52K 10-Q · filed 2025-05-15 | $84.11K derived: sum of 2 quarters · filed 2025-05-15 | $67.25K derived: sum of 3 quarters · filed 2025-05-15 | $117.44K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $51.60K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $34.73K derived: sum of 2 quarters · filed 2025-03-13 | $84.93K derived: sum of 3 quarters · filed 2025-03-13 | $79.82K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$16.87K 10-Q · filed 2024-11-13 | $33.33K derived: sum of 2 quarters · filed 2024-11-13 | $28.22K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $50.19K 10-Q · filed 2024-09-24 | $45.09K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |